We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Shoots Down Lipocine’s TRT Drug for Third Time
FDA Shoots Down Lipocine’s TRT Drug for Third Time
Lipocine has received a third complete response letter from the FDA for its novel oral testosterone replacement therapy Tlando for treatment of male hypogonadism.